Kathleen N. Moore

47.3k total citations · 12 hit papers
612 papers, 14.1k citations indexed

About

Kathleen N. Moore is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Kathleen N. Moore has authored 612 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Reproductive Medicine, 291 papers in Oncology and 115 papers in Obstetrics and Gynecology. Recurrent topics in Kathleen N. Moore's work include Ovarian cancer diagnosis and treatment (303 papers), PARP inhibition in cancer therapy (123 papers) and Endometrial and Cervical Cancer Treatments (109 papers). Kathleen N. Moore is often cited by papers focused on Ovarian cancer diagnosis and treatment (303 papers), PARP inhibition in cancer therapy (123 papers) and Endometrial and Cervical Cancer Treatments (109 papers). Kathleen N. Moore collaborates with scholars based in United States, United Kingdom and Canada. Kathleen N. Moore's co-authors include Colin Martindale, Michael J. Birrer, David M. O’Malley, Camille C. Gunderson, Ursula A. Matulonis, Robert L. Coleman, Robert S. Mannel, Bradley J. Monk, Theresa Thai and Joan L. Walker and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kathleen N. Moore

578 papers receiving 13.8k citations

Hit Papers

Recent advances and clini... 2016 2026 2019 2022 2022 2019 2019 2019 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recent advances and clinical applications of deep learning in medical image analysis
    2022 564 citations Kathleen N. Moore et al. profile →
  2. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    2019 377 citations Kathleen N. Moore, Angeles Alvarez Secord et al. profile →
  3. Antibody-Drug Conjugate-Based Therapeutics: State of the Science
    2019 323 citations Michael J. Birrer, Kathleen N. Moore et al. profile →
  4. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 319 citations Michael S. Gordon, Kathleen N. Moore et al. profile →
  5. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
    2019 299 citations R. Wendel Naumann, Ana Oaknin et al. Journal of Clinical Oncology profile →
  6. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
    2016 295 citations Robert L. Coleman, Kathleen N. Moore et al. Journal of Clinical Oncology profile →
  7. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
    2016 274 citations Robert L. Coleman, Kathleen N. Moore et al. Gynecologic Oncology profile →
  8. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
    2021 192 citations Gerald S. Falchook, Jeffrey R. Infante et al. profile →
  9. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    2021 186 citations Kathleen N. Moore, Amit M. Oza et al. profile →
  10. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    2023 81 citations Lucy Gilbert, Ana Oaknin et al. Gynecologic Oncology profile →
  11. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
    2024 58 citations Matthew A. Powell, Kathleen N. Moore et al. profile →
  12. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
    2025 15 citations Kathleen N. Moore et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathleen N. Moore United States 59 6.2k 4.8k 3.2k 2.8k 2.0k 612 14.1k
Ian Jacobs United Kingdom 68 3.2k 0.5× 7.1k 1.5× 5.7k 1.8× 3.5k 1.3× 2.1k 1.0× 325 17.1k
Michael Quinn Australia 61 3.7k 0.6× 3.2k 0.7× 3.0k 0.9× 2.2k 0.8× 1.7k 0.9× 342 12.7k
Robert L. Coleman United States 72 7.7k 1.3× 9.5k 2.0× 7.7k 2.4× 5.7k 2.1× 4.1k 2.1× 690 23.3k
Karen H. Lu United States 72 6.8k 1.1× 8.3k 1.7× 7.4k 2.3× 5.3k 1.9× 2.1k 1.0× 427 21.6k
Usha Menon United Kingdom 53 3.2k 0.5× 3.0k 0.6× 2.6k 0.8× 1.2k 0.4× 910 0.5× 305 10.6k
Ben Davidson Norway 63 3.8k 0.6× 2.4k 0.5× 6.9k 2.2× 1.2k 0.4× 921 0.5× 420 13.7k
Hitoshi Tsuda Japan 73 7.9k 1.3× 2.0k 0.4× 7.2k 2.3× 1.4k 0.5× 2.4k 1.2× 610 20.2k
Feng Gao United States 62 4.8k 0.8× 635 0.1× 2.9k 0.9× 982 0.4× 2.2k 1.1× 473 13.4k
Jae‐Hoon Kim South Korea 49 1.8k 0.3× 1.6k 0.3× 3.3k 1.0× 1.1k 0.4× 1.3k 0.6× 300 8.6k
Daniel S. Kapp United States 53 1.9k 0.3× 3.3k 0.7× 1.0k 0.3× 3.5k 1.3× 1.9k 1.0× 328 9.3k

Countries citing papers authored by Kathleen N. Moore

Since Specialization
Citations

This map shows the geographic impact of Kathleen N. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen N. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen N. Moore more than expected).

Fields of papers citing papers by Kathleen N. Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen N. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen N. Moore. The network helps show where Kathleen N. Moore may publish in the future.

Co-authorship network of co-authors of Kathleen N. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen N. Moore. A scholar is included among the top collaborators of Kathleen N. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen N. Moore. Kathleen N. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Ray-Coquard, Isabelle Laure, Debra L. Richardson, Kosei Hasegawa, et al.. (2024). REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).. Journal of Clinical Oncology. 42(16_suppl). TPS5625–TPS5625. 6 indexed citations
4.
5.
Powell, Matthew A., Virginia L. Filiaci, Martee L. Hensley, et al.. (2022). Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal of Clinical Oncology. 40(9). 968–977. 47 indexed citations
6.
7.
Moore, Kathleen N., Adam Asch, Víctor Moreno, et al.. (2022). 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A472–A473. 1 indexed citations
8.
Hong, David S., Kathleen N. Moore, Johanna C. Bendell, et al.. (2021). Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research. 27(7). 1864–1874. 37 indexed citations
9.
Oza, Amit M., Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, et al.. (2020). A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer. Clinical Cancer Research. 26(18). 4767–4776. 89 indexed citations
10.
O’Malley, David M., Ursula A. Matulonis, Michael J. Birrer, et al.. (2020). Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology. 157(2). 379–385. 113 indexed citations
11.
Papadopoulos, Kyriakos P., Melissa L. Johnson, A. Craig Lockhart, et al.. (2019). First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research. 26(5). 1025–1033. 50 indexed citations
12.
Naumann, R. Wendel, Robert L. Coleman, Jubilee Brown, & Kathleen N. Moore. (2019). Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecologic Oncology. 153(2). 436–444. 14 indexed citations
13.
Moore, Kathleen N. & Michael J. Birrer. (2018). Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. The Oncologist. 23(6). 697–703. 14 indexed citations
14.
Grisham, Rachel N., Kathleen N. Moore, Michael S. Gordon, et al.. (2018). Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Clinical Cancer Research. 24(22). 5525–5533. 22 indexed citations
15.
Bendell, Johanna C., Anna M. Varghese, David M. Hyman, et al.. (2018). A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research. 24(14). 3253–3262. 81 indexed citations
16.
Dey, Anindya, Shailendra Kumar Dhar Dwivedi, Kai Ding, et al.. (2018). Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Molecular Cancer Therapeutics. 17(10). 2136–2143. 14 indexed citations
17.
Hong, David S., Kathleen N. Moore, Manish R. Patel, et al.. (2018). Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research. 24(14). 3263–3272. 62 indexed citations
18.
19.
Gunderson, Camille C. & Kathleen N. Moore. (2015). BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Review of Molecular Diagnostics. 15(9). 1111–1116. 33 indexed citations
20.
Moore, Kathleen N.. (1992). al-Mughtaribun : law and the transformation of Muslim life in North America.. Scholarworks (University of Massachusetts Amherst). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian Jacobs Breakdown of academic impact, for papers by Michael Quinn Breakdown of academic impact, for papers by Robert L. Coleman Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Usha Menon Breakdown of academic impact, for papers by Ben Davidson Breakdown of academic impact, for papers by Hitoshi Tsuda Breakdown of academic impact, for papers by Feng Gao Breakdown of academic impact, for papers by Jae‐Hoon Kim Breakdown of academic impact, for papers by Daniel S. Kapp
Rankless by CCL
2026